Bruder Consulting & Venture Group 更名为 Dark Horse Consulting Regenerative Medicine

Core Insights - Dark Horse Consulting Group (DHCG) has announced the acquisition of Bruder Consulting & Venture Group (BCVG), enhancing its capabilities in the biotherapy sector, particularly in regenerative medicine, orthopedic, wound care, and plastic and reconstructive surgery markets [1][2] - The acquisition aims to accelerate the development and commercialization of biotherapeutic drugs, expanding DHCG's service offerings to include regenerative medicine, tissue repair, and biomaterials [2] - The integration of BCVG into DHCG is expected to enrich the company's expertise and improve its ability to provide comprehensive solutions to research institutions and investors [2] Company Overview - Dark Horse Consulting Group is a global consulting firm established in 2014, with offices in North America, Europe, and Asia-Pacific, focusing on accelerating the development and delivery of cell and gene therapies [3] - DHCG's consulting expertise spans the entire biopharmaceutical value chain, including strategic planning, operational management, quality control, regulatory affairs, manufacturing, modeling and analysis, supply chain management, market entry, and business optimization [3] - The company comprises three business units: DHC, BioTechLogic, and Converge Consulting, with BCVG now operating as a specialized department under DHC [3] Bruder Consulting & Venture Group Overview - Bruder Consulting & Venture Group is a full-service strategic consulting firm specializing in orthopedic, wound care, and plastic and reconstructive surgery markets, with significant expertise in the discovery, development, clinical design, and regulatory approval processes for bioproducts, medical devices, and combination products [4] - The BCVG team has completed over 900 projects for more than 150 companies globally and has led or supported licensing and acquisition transactions valued at over $2 billion [4]